Similar results are observed in the combined treatment of lovastatin (1 μM) and gefitinib inhibits proliferation, which promotes cell apoptosis, and reduces the AKT activity in K-ras mutant NSCLC cells compared with gefitinib alone [21]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.